<span item_type="fundamental" item_id="2dea354279fae0881c24cabcd1612c83" counter_id="ST/US/BDTX" env="prod"></span><span item_type="announcement" item_id="640940031611440769" env="prod"></span><p>Revenue: As of FY2025, the actual value is USD 70 M.</p><p>EPS: As of FY2025, the actual value is USD 0.39, missing the estimate of USD 0.4467.</p><p>EBIT: As of FY2025, the actual value is USD 8.461 M.</p><p></p><h4>Revenue</h4><ul><li><strong>License Revenue:</strong> Black Diamond Therapeutics, Inc. reported license revenue of $70,000 in 2025, compared to $0 in 2024.<span class="superscript" item_id="0" item_type="announcement_file" value="1" url="https://www.sec.gov/Archives/edgar/data/1701541/000170154126000009/bdtx-20251231.htm"></span></li></ul><h4>Operating Expenses</h4><ul><li><strong>Research and Development (R&amp;D) Expenses:</strong> R&amp;D expenses decreased by $17,754 to $33,558 in 2025 from $51,312 in 2024, primarily due to reductions in silevertinib (NSCLC) and BDTX-4933 R&amp;D expenses, and a decrease in personnel expenses within R&amp;D.<span class="superscript" item_id="0" item_type="announcement_file" value="1" url="https://www.sec.gov/Archives/edgar/data/1701541/000170154126000009/bdtx-20251231.htm"></span></li><li><strong>General and Administrative (G&amp;A) Expenses:</strong> G&amp;A expenses decreased by $10,897 to $16,572 in 2025 from $27,469 in 2024, attributed to operational and workforce efficiencies from a corporate restructuring in late 2024.<span class="superscript" item_id="0" item_type="announcement_file" value="1" url="https://www.sec.gov/Archives/edgar/data/1701541/000170154126000009/bdtx-20251231.htm"></span></li><li><strong>Impairment of right-of-use assets and property and equipment:</strong> An impairment charge of $7,348 was recorded in 2025, compared to $0 in 2024.<span class="superscript" item_id="0" item_type="announcement_file" value="1" url="https://www.sec.gov/Archives/edgar/data/1701541/000170154126000009/bdtx-20251231.htm"></span></li><li><strong>Total Operating Expenses:</strong> Total operating expenses decreased by $21,303 to $57,478 in 2025 from $78,781 in 2024.<span class="superscript" item_id="0" item_type="announcement_file" value="1" url="https://www.sec.gov/Archives/edgar/data/1701541/000170154126000009/bdtx-20251231.htm"></span></li></ul><h4>Income/Loss from Operations</h4><ul><li><strong>Income (Loss) from Operations:</strong> Black Diamond Therapeutics, Inc. reported income from operations of $12,522 in 2025, an increase of $91,303 from a loss of -$78,781 in 2024.<span class="superscript" item_id="0" item_type="announcement_file" value="1" url="https://www.sec.gov/Archives/edgar/data/1701541/000170154126000009/bdtx-20251231.htm"></span></li></ul><h4>Other Income (Expense)</h4><ul><li><strong>Interest Income:</strong> Interest income increased by $1,879 to $4,061 in 2025 from $2,182 in 2024.<span class="superscript" item_id="0" item_type="announcement_file" value="1" url="https://www.sec.gov/Archives/edgar/data/1701541/000170154126000009/bdtx-20251231.htm"></span></li><li><strong>Other Income (Expense):</strong> Other income (expense) decreased by $1,139 to $5,784 in 2025 from $6,923 in 2024.<span class="superscript" item_id="0" item_type="announcement_file" value="1" url="https://www.sec.gov/Archives/edgar/data/1701541/000170154126000009/bdtx-20251231.htm"></span></li><li><strong>Total Other Income (Expense), Net:</strong> Total other income (expense), net, increased by $740 to $9,845 in 2025 from $9,105 in 2024.<span class="superscript" item_id="0" item_type="announcement_file" value="1" url="https://www.sec.gov/Archives/edgar/data/1701541/000170154126000009/bdtx-20251231.htm"></span></li></ul><h4>Net Income (Loss)</h4><ul><li><strong>Net Income (Loss):</strong> Black Diamond Therapeutics, Inc. recorded a net income of $22,367 in 2025, compared to a net loss of -$69,676 in 2024.<span class="superscript" item_id="0" item_type="announcement_file" value="1" url="https://www.sec.gov/Archives/edgar/data/1701541/000170154126000009/bdtx-20251231.htm"></span></li><li><strong>Accumulated Deficit:</strong> The accumulated deficit stood at -$464,740 as of December 31, 2025.<span class="superscript" item_id="0" item_type="announcement_file" value="1" url="https://www.sec.gov/Archives/edgar/data/1701541/000170154126000009/bdtx-20251231.htm"></span></li></ul><h4>Cash Flows</h4><ul><li><strong>Cash provided by (used in) Operating Activities:</strong> Cash provided by operating activities was $29,614 in 2025, a significant improvement from -$62,303 used in 2024.<span class="superscript" item_id="0" item_type="announcement_file" value="1" url="https://www.sec.gov/Archives/edgar/data/1701541/000170154126000009/bdtx-20251231.htm"></span></li><li><strong>Cash provided by (used in) Investing Activities:</strong> Cash used in investing activities was -$44,905 in 2025, compared to $16,968 provided in 2024.<span class="superscript" item_id="0" item_type="announcement_file" value="1" url="https://www.sec.gov/Archives/edgar/data/1701541/000170154126000009/bdtx-20251231.htm"></span></li><li><strong>Cash provided by (used in) Financing Activities:</strong> Cash used in financing activities was -$146 in 2025, compared to $25,547 provided in 2024.<span class="superscript" item_id="0" item_type="announcement_file" value="1" url="https://www.sec.gov/Archives/edgar/data/1701541/000170154126000009/bdtx-20251231.htm"></span></li><li><strong>Net increase (decrease) in cash and cash equivalents:</strong> The net decrease in cash and cash equivalents was -$15,437 in 2025, an improvement from a decrease of -$19,788 in 2024.<span class="superscript" item_id="0" item_type="announcement_file" value="1" url="https://www.sec.gov/Archives/edgar/data/1701541/000170154126000009/bdtx-20251231.htm"></span></li></ul><h4>Key Financial Position Data</h4><ul><li><strong>Cash, Cash Equivalents and Investments:</strong> Black Diamond Therapeutics, Inc. held $128,700 in cash, cash equivalents, and investments as of December 31, 2025.<span class="superscript" item_id="0" item_type="announcement_file" value="1" url="https://www.sec.gov/Archives/edgar/data/1701541/000170154126000009/bdtx-20251231.htm"></span></li></ul><h4>Unique Metrics</h4><ul><li><strong>BDTX-4933 License Agreement:</strong> Black Diamond Therapeutics, Inc. received an upfront payment of $70.0 million in March 2025 from Servier for the global license of BDTX-4933.<span class="superscript" item_id="0" item_type="announcement_file" value="1" url="https://www.sec.gov/Archives/edgar/data/1701541/000170154126000009/bdtx-20251231.htm"></span></li><li>The company is eligible to receive up to $710.0 million in development and commercial sales milestone payments, plus tiered royalties, from the Servier agreement.<span class="superscript" item_id="0" item_type="announcement_file" value="1" url="https://www.sec.gov/Archives/edgar/data/1701541/000170154126000009/bdtx-20251231.htm"></span></li></ul><h4>Outlook / Guidance</h4><p>Black Diamond Therapeutics, Inc. projects its $128.7 million in cash, cash equivalents, and investments as of December 31, 2025, will fund operations into the second half of 2028, though additional capital will be required for regulatory approvals or potential in-licenses/acquisitions due to anticipated increased expenses from advancing silevertinib clinical trials.<span class="superscript" item_id="0" item_type="announcement_file" value="1" url="https://www.sec.gov/Archives/edgar/data/1701541/000170154126000009/bdtx-20251231.htm"></span> The company plans to present updated Phase 2 NSCLC trial results and initiate a randomized Phase 2 trial for newly diagnosed EGFR-altered GBM patients in the second quarter of 2026, with interim PFS analysis for the GBM trial expected in the first half of 2028.<span class="superscript" item_id="0" item_type="announcement_file" value="1" url="https://www.sec.gov/Archives/edgar/data/1701541/000170154126000009/bdtx-20251231.htm"></span></p>

Black Diamond Therapeutics | 10-K: FY2025 Revenue: USD 70 M